Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 2/20 | 0.37 |
| ▸ | FNTB | P49356 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716630 | 0.90 | HTR2A (0.41) | HTR2AHTR2CHTR2BBDKRB1FAAH | |
| SCHEMBL4715875 | 0.88 | NPBWR1 (0.42) | GPR119BDKRB1KDM1AUSP30RXFP1 | |
| SCHEMBL5632155 | 0.84 | BDKRB1 (0.48) | HTR2AHTR2CHTR2BBDKRB1 | |
| SCHEMBL4716498 | 0.84 | AKT1 (0.41) | HTR2AHTR2CHTR2BBDKRB1 | |
| SCHEMBL4712314 | 0.77 | BDKRB1 (0.49) | HTR2AHTR2CHTR2BBDKRB1 | |
| SCHEMBL4714752 | 0.76 | HTR2A (0.40) | HTR2AHTR2CHTR2BBDKRB1KDM1A | |
| SCHEMBL4791583 | 0.75 | GPR119 (0.46) | GPR119HTR2AHTR2CHTR2BBDKRB1 | |
| SCHEMBL4711961 | 0.72 | HTR6 (0.44) | HTR2AHTR2CHTR2BBDKRB1 | |
| SCHEMBL5630710 | 0.71 | BDKRB1 (0.48) | HTR2AHTR2CHTR2BBDKRB1 | |
| SCHEMBL4717297 | 0.71 | PARP1 (0.40) | HTR2AHTR2CHTR2BBDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | GPR119 165/4885HTR2A 742/4885HTR2C 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.